Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study

Background: A new-generation coronary sirolimus eluting-stent(SES), whose novel characteristics are summarized in ultra-thin oval-shaped hydrodynamic struts (68 mu m) and abluminal drug release with permanent fluoropolymer containing the platelet aggregation inhibitor triflusal, showed low target le...

Descripción completa

Detalles Bibliográficos
Autores: Vicente, JAL, Laso, FS, Sandoval, JMC, Cueva, JRR, Menchero, AG, Gómez-Hospital, JA, Guerrero, AP, Martinez, SS, Portalés, JF, Romani, S, Del Blanco, BG, Sánchez, RO, Carrillo, CU, Roman, KGS, Vinhas, H, Alvarez, BC, Fores, JS, Arrieta, MT, Bosco, AT, Bermúdez, EP, Castro, JJM, de Poveda, FLR, de Prado, AP, Hernández, JMD
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:dnet:r-fisabio___::0bce6afc8261664b51db71d155a924ee
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/20841
Access Level:acceso abierto
Palabra clave:Coronary artery disease
Percutaneous coronary intervention
Drug-eluting stents
Target lesion failure
Stent thrombosis
id ES_9d6097fb6a8a95c80809a493eec55eef
oai_identifier_str oai:dnet:r-fisabio___::0bce6afc8261664b51db71d155a924ee
network_acronym_str ES
network_name_str España
repository_id_str
spelling Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 studyVicente, JALLaso, FSSandoval, JMCCueva, JRRMenchero, AGGómez-Hospital, JAGuerrero, APMartinez, SSPortalés, JFRomani, SDel Blanco, BGSánchez, ROCarrillo, CURoman, KGSVinhas, HAlvarez, BCFores, JSArrieta, MTBosco, ATBermúdez, EPCastro, JJMde Poveda, FLRde Prado, APHernández, JMDCoronary artery diseasePercutaneous coronary interventionDrug-eluting stentsTarget lesion failureStent thrombosisBackground: A new-generation coronary sirolimus eluting-stent(SES), whose novel characteristics are summarized in ultra-thin oval-shaped hydrodynamic struts (68 mu m) and abluminal drug release with permanent fluoropolymer containing the platelet aggregation inhibitor triflusal, showed low target lesion failure(TLF) and absence of stent thrombosis(ST) at 1 year in a first-in-human study. Long-term clinical efficacy is unknown. We aim to investigate lo ng-term clinical efficacy of this new SES in a real-world population undergoing PCI for native coronary artery. Methods: VELAZQUEZ-EPIC26 is a prospective, observational and multicentre study of a large cohort undergoing PCI with the new SES (ihtDEStinyTM). Primary endpoint was TLF at 2 years (composite of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization). Secondary clinical safety and efficacy endpoints included definitive or probable ST, target vessel failure (TVF), major adverse cardiac events (MACE), and BARC 3-5 bleeding. Results: Between 2021 and 2023, 406 patients (mean age 65 +/- 11 years, 75 % males, 26 % diabetes) were included. 519 SES were implanted over 482 target lesions. Mean stent diameter and length were 3.03 +/- 0.49 mm and 22 +/- 7,6 mm respectively. Procedural success rate was 97.3 %. TLF at 2 years was 2,2 % (n = 9). There were 3 cardiovas-cular deaths (0,7 %), none related to SES complications. 1 very late definite stent thrombosis was reported (0,2 %, n = 1). TVF, MACE and BARC 3-5 bleeding rates at years were 3 % (n = 12), 3,2 % (n = 13) and 3,5% (n = 14) respec-tively. Conclusions: Ina large real-world population undergoing PCI for native coronary artery, anew hydrodynamic ultra-thin strut SES with abluminal permanent fluoropolymer containing triflusal shows low TLF and very low ST rates at 2 years.ELSEVIER INC2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/20841Cardiovascular Revascularization MedicineISSN: 15538389ISSNe: 18780938reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:dnet:r-fisabio___::0bce6afc8261664b51db71d155a924ee2026-06-11T12:45:17Z
dc.title.none.fl_str_mv Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
spellingShingle Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
Vicente, JAL
Coronary artery disease
Percutaneous coronary intervention
Drug-eluting stents
Target lesion failure
Stent thrombosis
title_short Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title_full Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title_fullStr Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title_full_unstemmed Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title_sort Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
dc.creator.none.fl_str_mv Vicente, JAL
Laso, FS
Sandoval, JMC
Cueva, JRR
Menchero, AG
Gómez-Hospital, JA
Guerrero, AP
Martinez, SS
Portalés, JF
Romani, S
Del Blanco, BG
Sánchez, RO
Carrillo, CU
Roman, KGS
Vinhas, H
Alvarez, BC
Fores, JS
Arrieta, MT
Bosco, AT
Bermúdez, EP
Castro, JJM
de Poveda, FLR
de Prado, AP
Hernández, JMD
author Vicente, JAL
author_facet Vicente, JAL
Laso, FS
Sandoval, JMC
Cueva, JRR
Menchero, AG
Gómez-Hospital, JA
Guerrero, AP
Martinez, SS
Portalés, JF
Romani, S
Del Blanco, BG
Sánchez, RO
Carrillo, CU
Roman, KGS
Vinhas, H
Alvarez, BC
Fores, JS
Arrieta, MT
Bosco, AT
Bermúdez, EP
Castro, JJM
de Poveda, FLR
de Prado, AP
Hernández, JMD
author_role author
author2 Laso, FS
Sandoval, JMC
Cueva, JRR
Menchero, AG
Gómez-Hospital, JA
Guerrero, AP
Martinez, SS
Portalés, JF
Romani, S
Del Blanco, BG
Sánchez, RO
Carrillo, CU
Roman, KGS
Vinhas, H
Alvarez, BC
Fores, JS
Arrieta, MT
Bosco, AT
Bermúdez, EP
Castro, JJM
de Poveda, FLR
de Prado, AP
Hernández, JMD
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Coronary artery disease
Percutaneous coronary intervention
Drug-eluting stents
Target lesion failure
Stent thrombosis
topic Coronary artery disease
Percutaneous coronary intervention
Drug-eluting stents
Target lesion failure
Stent thrombosis
description Background: A new-generation coronary sirolimus eluting-stent(SES), whose novel characteristics are summarized in ultra-thin oval-shaped hydrodynamic struts (68 mu m) and abluminal drug release with permanent fluoropolymer containing the platelet aggregation inhibitor triflusal, showed low target lesion failure(TLF) and absence of stent thrombosis(ST) at 1 year in a first-in-human study. Long-term clinical efficacy is unknown. We aim to investigate lo ng-term clinical efficacy of this new SES in a real-world population undergoing PCI for native coronary artery. Methods: VELAZQUEZ-EPIC26 is a prospective, observational and multicentre study of a large cohort undergoing PCI with the new SES (ihtDEStinyTM). Primary endpoint was TLF at 2 years (composite of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization). Secondary clinical safety and efficacy endpoints included definitive or probable ST, target vessel failure (TVF), major adverse cardiac events (MACE), and BARC 3-5 bleeding. Results: Between 2021 and 2023, 406 patients (mean age 65 +/- 11 years, 75 % males, 26 % diabetes) were included. 519 SES were implanted over 482 target lesions. Mean stent diameter and length were 3.03 +/- 0.49 mm and 22 +/- 7,6 mm respectively. Procedural success rate was 97.3 %. TLF at 2 years was 2,2 % (n = 9). There were 3 cardiovas-cular deaths (0,7 %), none related to SES complications. 1 very late definite stent thrombosis was reported (0,2 %, n = 1). TVF, MACE and BARC 3-5 bleeding rates at years were 3 % (n = 12), 3,2 % (n = 13) and 3,5% (n = 14) respec-tively. Conclusions: Ina large real-world population undergoing PCI for native coronary artery, anew hydrodynamic ultra-thin strut SES with abluminal permanent fluoropolymer containing triflusal shows low TLF and very low ST rates at 2 years.
publishDate 2026
dc.date.none.fl_str_mv 2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/20841
url https://fisabio.portalinvestigacion.com/publicaciones/20841
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER INC
publisher.none.fl_str_mv ELSEVIER INC
dc.source.none.fl_str_mv Cardiovascular Revascularization Medicine
ISSN: 15538389
ISSNe: 18780938
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414738023153664
score 15,81155

Similares en LA Referencia